Factors associated with renal impairment in Chinese patients with non-valvular AF and without an established renal disease: a cross-sectional study

References

• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8):983–988.
   PubMed Web of Science ®Google Scholar
• Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis risk in communities (ARIC) study. Circulation. 2011;123(25):2946–2953.
   Web of Science ®Google Scholar
• Horio T, Iwashima Y, Kamide K, et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. Journal of Hypertension. 2010;28(8):1738–1744.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Watanabe T, Sasaki S, et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. American Heart Journal. 2009;158(4):629–636
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Chang KH, et al. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ. 2010;341:c4249.
   PubMed Web of Science ®Google Scholar
• Niu J, Shah MK, Perez JJ, et al. Dialysis modality and incident atrial fibrillation in older patients with ESRD. Am J Kidney Dis. 2019;73(3):324–331.
   PubMed Web of Science ®Google Scholar
• Shen CH, Zheng CM, Kiu KT, et al. Increased risk of atrial fibrillation in end-stage renal disease patients on dialysis: A nationwide, population-based study in Taiwan. Medicine (Baltimore). 2016;95(25):e3933.
   PubMed Web of Science ®Google Scholar
• Kunwar SRijal J, et al. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest. 2016;149(4):951–959.
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625–635.
   PubMed Web of Science ®Google Scholar
• Di Lullo L, Rivera R, Barbera V, et al. Sudden cardiac death and chronic kidney disease: from pathophysiology to treatment strategies. Int J Cardiol. 2016;217:16–27.
   PubMed Web of Science ®Google Scholar
• Di Lullo L, Tripepi G, Ronco C, et al. Cardiac valve calcification and use of anticoagulants: preliminary observation of a potentially modifiable risk factor. Int J Cardiol. 2019;278:243–249.
   PubMed Web of Science ®Google Scholar
• Di Lullo L, Ronco C, Cozzolino M, et al. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Thromb Res. 2017;155:38–47.
   PubMed Web of Science ®Google Scholar
• Di Lullo L, Tripepi G, Ronco C, et al. Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data. J Nephrol. 2018;31(5):751–756.
   PubMed Web of Science ®Google Scholar
• Ravera M, Bussalino E, Paoletti E, et al. Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: do we need a novel risk score calculator? Int J Cardiol. 2019;274:179–185.
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén Lars E, Cannom David S, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary. Circulation. 2006;114(7):700–752.
   Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine. 2009;150(9):604.
   PubMed Web of Science ®Google Scholar
• NK. K/doqi clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
   PubMed Web of Science ®Google Scholar
• Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12(10):610–623.
   PubMed Web of Science ®Google Scholar
• Bukowska A, Lendeckel U, Krohn A, et al. Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney. Europace. 2008;10(10):1212–1217.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang XD, Liu X, et al. Renal function after repeat catheter ablation for long-standing persistent atrial fibrillation: low CHA2DS2-VASc score and sinus rhythm predict improved renal function. Herz. 2016;41(4):331–341.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Takahashi A, Kuwahara T, et al. Renal function after catheter ablation of atrial fibrillation. Circulation. 2011;124(22):2380–2387.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–1951.
   PubMed Web of Science ®Google Scholar
• Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2):131–140.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860.
   PubMed Web of Science ®Google Scholar
• National Guideline C. Hypertension in adults: diagnosis and management. London: National Institute for Health and Care Excellence (UK); 2019.
   Google Scholar
• Lesogor A, Cohn JN, Latini R, et al. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. Eur J Heart Fail. 2013;15(11):1236–1244.
   PubMedGoogle Scholar
• Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ (Clin Res Ed). 2017;356:j791–j91.
   PubMedGoogle Scholar
• Power A, Epstein D, Cohen D, et al. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke. Cerebrovasc Dis. 2013;35(1):45–52.
   PubMed Web of Science ®Google Scholar
• Kamouchi M, Sakai H, Kiyohara Y, et al. Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka stroke registry. J Stroke Cerebrovasc Dis. 2013;22(8):e470–e76.
   PubMed Web of Science ®Google Scholar
• Tsagalis G, Akrivos T, Alevizaki M, et al. Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality. Nephrol Dialysis Trans. 2009;24(1):194–200.
   PubMed Web of Science ®Google Scholar